An established global healthcare business is building a new aesthetics franchise from scratch, and extending its portfolio through external innovation. This is a genuine blank page: not maintaining an existing business, but building the operating model, partnerships and pipeline that will carry it forward. Real autonomy, direct visibility to senior leadership, and the ambition to become a top player in medical aesthetics.
You will be the central integrator, the person who takes an externally sourced asset from evaluation through to launch.
The Role:
Own the programme plan for an asset moving through development, registration and launch: timelines, milestones, risk and budget.
Lead a cross-functional team spanning R&D, regulatory, quality, medical and commercial, without direct line authority.
Manage external partners, developers, licensors, manufacturers and CDMOs, holding them to scope, timeline and quality.
Support the evaluation of future assets alongside business development, bringing technical and programme judgement to the assessment.
Not run regulatory submissions or clinical trials directly. Those sit with specialist teams; you carry overall accountability for the programme reaching launch.
What we are looking for:
Background in HA dermal fillers, botulinum toxins, injectable biostimulators, or closely adjacent device-led aesthetic or medical device products. Roughly 8-12 years, Manager to Director level.
A track record supporting or leading a device or injectable product through development and registration (EU MDR, FDA or equivalent), whether from within a single function or across the full arc.
Comfortable managing external development and manufacturing partners.
Experience leading, or driving to success, a cross-functional team without formal authority.
Genuine curiosity beyond your own specialism, with a record of stepping outside it.
FDA or US regulatory exposure a strong plus, not a requirement.
A relevant scientific or technical degree.
This is the first hire into a franchise that will grow asset by asset. As the portfolio ex
